SpringWorks Therapeutics Share Holder Equity 2019-2022 | SWTX

SpringWorks Therapeutics share holder equity from 2019 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
SpringWorks Therapeutics Annual Share Holder Equity
(Millions of US $)
2021 $422
2020 $557
2019 $322
2018 $44
SpringWorks Therapeutics Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $377
2021-12-31 $422
2021-09-30 $467
2021-06-30 $497
2021-03-31 $535
2020-12-31 $557
2020-09-30 $273
2020-06-30 $291
2020-03-31 $308
2019-12-31 $322
2019-09-30 $337
2019-06-30 $0
2019-03-31 $0
2018-12-31
2018-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.838B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00